Insights

Innovative Platform Launch LiVeritas Biosciences recently launched the beta version of their AI-powered LiLii platform, which offers an integrated laboratory ecosystem designed to streamline drug development workflows. This presents opportunities to offer complementary automation solutions, AI enhancements, or workflow optimization tools to enhance their platform capabilities.

Focus on Digital Transformation The company's emphasis on digital transformation and advanced software solutions indicates a strong demand for digital tools that improve efficiency and data management in biopharma research. Sales prospects include data analytics, cloud-based integration services, and laboratory information management systems tailored for biotech R&D.

Mass Spectrometry Services LiVeritas offers Mass Spec as a Service (MSaaS), targeting early-stage drug testing and diagnostics. Opportunities exist to provide complementary instrumentation, workflow automation, or related analytical technologies that support their existing service suite and expand their analytical capacity.

Growing Industry Presence Given their recent high-profile product launches and focus on drug development efficiency, LiVeritas is positioned for growth within the biotech R&D sector. Engagement opportunities include sales of laboratory automation tools, AI software solutions, and niche analytical instruments aimed at biopharma innovators.

Market Expansion Potential With a focus on speeding up drug research processes for biopharma partners, there is potential for building strategic partnerships with companies providing complementary biotech infrastructure, cloud data services, or integrated laboratory solutions to support their expanding platform ecosystem.

LiVeritas Biosciences, Inc. Tech Stack

LiVeritas Biosciences, Inc. uses 8 technology products and services including jQuery CDN, Cookiebot, Swiper, and more. Explore LiVeritas Biosciences, Inc.'s tech stack below.

  • jQuery CDN
    Content Delivery Network
  • Cookiebot
    Cookie Compliance
  • Swiper
    Javascript Libraries
  • Polyfill
    Javascript Libraries
  • reCAPTCHA
    Security
  • HSTS
    Security
  • X-Content-Type-Options
    Web & Portal Technology
  • Google Analytics
    Web Analytics

Media & News

LiVeritas Biosciences, Inc.'s Email Address Formats

LiVeritas Biosciences, Inc. uses at least 1 format(s):
LiVeritas Biosciences, Inc. Email FormatsExamplePercentage
First@liveritas.bioJohn@liveritas.bio
50%
First@liveritas.bioJohn@liveritas.bio
50%

Frequently Asked Questions

Where is LiVeritas Biosciences, Inc.'s headquarters located?

Minus sign iconPlus sign icon
LiVeritas Biosciences, Inc.'s main headquarters is located at South San Francisco, California 94080 United States. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is LiVeritas Biosciences, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
LiVeritas Biosciences, Inc.'s official website is liveritas.bio and has social profiles on LinkedInCrunchbase.

What is LiVeritas Biosciences, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
LiVeritas Biosciences, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does LiVeritas Biosciences, Inc. have currently?

Minus sign iconPlus sign icon
As of February 2026, LiVeritas Biosciences, Inc. has approximately 10 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Head Of Product & Automation: N. S. C.Head Of Software Engineering: J. A.. Explore LiVeritas Biosciences, Inc.'s employee directory with LeadIQ.

What industry does LiVeritas Biosciences, Inc. belong to?

Minus sign iconPlus sign icon
LiVeritas Biosciences, Inc. operates in the Biotechnology Research industry.

What technology does LiVeritas Biosciences, Inc. use?

Minus sign iconPlus sign icon
LiVeritas Biosciences, Inc.'s tech stack includes jQuery CDNCookiebotSwiperPolyfillreCAPTCHAHSTSX-Content-Type-OptionsGoogle Analytics.

What is LiVeritas Biosciences, Inc.'s email format?

Minus sign iconPlus sign icon
LiVeritas Biosciences, Inc.'s email format typically follows the pattern of First@liveritas.bio. Find more LiVeritas Biosciences, Inc. email formats with LeadIQ.

When was LiVeritas Biosciences, Inc. founded?

Minus sign iconPlus sign icon
LiVeritas Biosciences, Inc. was founded in 2020.

LiVeritas Biosciences, Inc.

Biotechnology ResearchCalifornia, United States2-10 Employees

LiVeritas Biosciences enables biopharma companies to fast track drug research & development (R&D) process through mass spectrometry (MS) and digital transformation. We offer unparalleled sense of urgency and quality of work to empower our partners in delivering patient-centric outcomes through: 
•	Curated analytical test packages effective in rapidly advancing drug candidates in the development pipeline including (1) drug design optimization, (2) process development and characterization, (3) accelerating novel drug candidates path to Investigational New Drug (IND)
•	Partner-centric software solutions that streamlines analytical operations, CMC strategies, and drug product knowledge management; and 
•	Industry expertise with milestone focused biotech startup backgrounds grounded in big biopharma core competencies.

Section iconCompany Overview

Headquarters
South San Francisco, California 94080 United States
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2020
Employees
2-10

Section iconFunding & Financials

  • $1M$10M

    LiVeritas Biosciences, Inc.'s revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    LiVeritas Biosciences, Inc.'s revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.